Tusamitamab Ravtansine for previously treated advanced Non-Small-Cell Lung Cancer

Tusamitamab ravtansine is being developed for previously treated, CEACAM5 positive metastatic non-squamous non-small-cell lung cancer (NSCLC). This form of lung cancer develops in the flat cells that cover the surface of the airways and tends to grow near the centre of the lung. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to the liver, adrenal glands, bones, and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. There is therefore the need for additional treatment options.